US Patent Issued to Zymedi on July 14 for "Antibody for specifically binding to lysyl-tRNA synthetase N-terminal domain exposed to extracellular membrane" (South Korean Inventors)

ALEXANDRIA, Va., July 14 -- United States Patent no. 12,679,903, issued on July 14, was assigned to Zymedi Co. Ltd. (Incheon, South Korea).

"Antibody for specifically binding to lysyl-tRNA synthetase N-terminal domain exposed to extracellular membrane" was invented by Sunghoon Kim (Gyeonggi-Do, South Korea) and Nam Hoon Kwon (Gyeonggi-do, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to an antibody that specifically binds to the lysyl-tRNA synthase N-terminal domain exposed to the extracellular membrane, more specifically, it specifically binds to the lysyl-tRNA synthetase (KRS, Lysyl-tRNA synthetase)N-terminal domain exposed to the extracellular membrane having a s...